- Home
- GLOB vs COLL Comparison
GLOB vs COLL Comparison
Compare GLOB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLOB | COLL |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GLOB | COLL |
|---|---|---|
| Price | $36.24 | $22.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 8 |
| Target Price | ★ $51.23 | $49.00 |
| AVG Volume (30 Days) | ★ 820.9K | 752.3K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.84 |
| Revenue Next Year | $2.08 | $1.25 |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $27.56 | $21.43 |
| 52 Week High | $72.10 | $50.79 |
Technical Indicators
Market Signals| Indicator | GLOB | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 35.11 |
| Support Level | $35.68 | $21.54 |
| Resistance Level | $38.88 | $23.69 |
| Average True Range (ATR) | 1.34 | 0.75 |
| MACD | 0.19 | 0.24 |
| Stochastic Oscillator | 56.82 | 32.96 |
Price Performance
Historical ComparisonAbout GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.